News from epic sciences A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 28, 2018, 09:00 ET Epic Sciences to Present Data at SABCS 2018

Epic Sciences, Inc. (Epic) announced today that they will be presenting new data on inter- and intra-patient phenotypic heterogeneity and the use of...


Jan 04, 2018, 08:00 ET Epic Sciences To Present At The 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit

Epic Sciences, Inc. (Epic) announces that it is one of six companies chosen to present at the second annual CTIC Capital Cross-Border China-US...


Apr 28, 2017, 07:00 ET Epic Sciences Announces Completion of $40 Million Series D Financing

Epic Sciences (Epic) announced today that the company has completed a $40 million Series D financing led by Hermed Capital. Altos Capital Partners,...


Jan 06, 2017, 08:00 ET Study from MSK and Epic Sciences Shows Only Nuclear-localized AR-V7 Is Predictive of Therapy Benefit for Patients with Metastatic Prostate Cancer

Investigators from Memorial Sloan Kettering Cancer Center (MSK) and Epic Sciences published findings in European Urology, that only nuclear...


Nov 16, 2016, 02:00 ET Epic Sciences Validates Single CTC Sequencing, Identifies Clonal Heterogeneity in Metastatic Cancer

Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells...


Nov 16, 2016, 02:00 ET Liquid Biopsy Biomarker Identifies Patients with Improved Response to PARP Inhibition in Metastatic Castrate Resistant Prostate Cancer

Epic Sciences announced findings demonstrating a circulating tumor cell (CTC) biomarker can identify patients with metastatic castrate resistant...


Jun 24, 2016, 08:02 ET Epic Sciences Introduces Sensitive HRD Liquid Biopsy Test for PARP Inhibitor Clinical Trials

Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous...


Jun 04, 2016, 08:02 ET Presence of AR-V7 in Circulating Tumor Cells Validated as Predictive Biomarker for Advanced Prostate Cancer Treatment by Memorial Sloan Kettering and Epic Sciences

Detecting AR-V7 positive tumor cells circulating in the blood of an advanced prostate cancer patient predicts that he will not only fail the...


Jan 11, 2016, 08:01 ET Epic Sciences Receives CAP Accreditation

Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego ...


Dec 11, 2015, 08:01 ET Epic Sciences Enters into 35th Pharma Collaboration to Advance Companion Diagnostics for New Targeted Therapeutics

Epic Sciences, a private biotech company that develops novel diagnostics to personalize and advance the treatment and management of cancer, announced ...


Nov 11, 2015, 08:05 ET Circulating tumor cells (CTCs) in patients' blood detected by Epic Sciences are an "accurate representation" of genetic aberrations found in fresh metastatic tumor samples

Most men with advanced prostate cancer, whether initially treated through surgical or chemical castration, eventually develop drug-resistant tumors....


Nov 02, 2015, 08:02 ET Epic Sciences' Platform Capable of Single Cell CTC Identification Sequencing in Late Stage, Metastatic Cancer

After successive cancer therapies, multiple subpopulations of cancer cells arise, each with divergent genetic aberrations that may confer drug...


Jul 07, 2015, 08:00 ET Epic Sciences Expands Partnership with LabCorp to Provide Circulating Tumor Cell Analysis and Support Oncology Clinical Trials in Asia

Epic Sciences (Epic) announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) to provide circulating tumor ...


Apr 16, 2015, 08:00 ET Epic Sciences Demonstrates Single Cell Genetic Analysis for Circulating Tumor Cells

Epic Sciences announced today that its no cell left behind™ technology has successfully integrated single cell isolation and downstream genetic...


Mar 09, 2015, 08:00 ET Epic Sciences and The Prostate Cancer Clinical Trials Consortium Collaborate to Advance Therapeutic Development

Epic Sciences and The Prostate Cancer Clinical Trials Consortium (PCCTC), the leading consortium for Phase 1/2 and Phase 2 clinical trials in...


Feb 26, 2015, 08:00 ET Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference

Epic Sciences announced today that President and CEO Murali Prahalad, Ph.D. will present at the 35th Annual Cowen and Company Health Care Conference...


Feb 25, 2015, 08:00 ET Epic Sciences Appoints Chris Bernard as Chief Commercial Officer

Epic Sciences announced today the appointment of Chris Bernard as chief commercial officer. Mr. Bernard has more than 20 years of experience as a...


Feb 23, 2015, 05:00 ET Epic Sciences Announces Presentation of Three Studies on Novel CTC Liquid Biopsy Assays for Metastatic Prostate Cancers and Bladder Cancers at 2015 ASCO GU Cancer Symposium

Epic Sciences announced today that results from studies in metastatic castration resistant prostate cancer (mCRPC), neuroendocrine prostate cancer...


Jan 26, 2015, 08:00 ET Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers

Epic Sciences, a precision diagnostics company dedicated to improving the treatment of cancer, today announced that Murali Prahalad, Ph.D., president ...


Jan 08, 2015, 08:00 ET Epic Sciences Receives CLIA Certification for its Cancer Diagnostics Laboratory

Epic Sciences announced today that the company has received certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under...


Nov 26, 2014, 07:00 ET Epic Sciences to Present at the Piper Jaffray Healthcare Conference

Epic Sciences, a precision diagnostics company dedicated to improving the treatment of cancer, today announced that Murali Prahalad, Ph.D., president ...


Nov 17, 2014, 08:00 ET Epic Sciences to Present Data on a Combination CTC and cfDNA Assay for Molecular Targets of Non-Small Cell Lung Cancer Therapies at the 26th EORTC-NCI-AACR Symposium

Epic Sciences will present data describing the detection of clinically actionable non-small cell lung cancer (NSCLC) biomarkers, including EGFR,...


Nov 13, 2014, 08:00 ET Epic Sciences Appoints Toni Wayne as Vice President of Human Resources

Epic Sciences announced today the appointment of Toni Wayne as vice president of human resources. Ms. Wayne has more than 20 years of experience as a ...


Nov 12, 2014, 08:00 ET Epic Sciences to Present on Characterizing PD-L1 in Circulating Tumor Cells of Non-Small Cell Lung Cancer Patients at the 26th EORTC-NCI-AACR Symposium

Epic Sciences will present an analysis of PD-L1 protein expression on circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients....


Oct 20, 2014, 08:00 ET Epic Sciences Appoints Michael Giske as Chief Information Officer

Epic Sciences announced today the appointment of Michael Giske as chief information officer. Mr. Giske has more than 25 years of defining, designing...